An extended-release once-daily oral capsule formulation of viloxazine (viloxazine ER; Qelbree^(®)), a norepinephrine reuptake inhibitor and serotonin receptor modulator, has been approved in the USA for the treatment of attention-deficit/hyperactivity disorder (ADHD) in paediatric patients and adults. This article reviews its use in adults with ADHD, with a brief overview of its pharmacological properties. In a randomized, double-blind, placebo-controlled, 6-week phase 3 trial, viloxazine ER…
